Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Multiple Myeloma: Update Bulletin [September 2017]

Product Code:
Publication Date:
September 2017

This edition presents key opinion leader (KOL) views on recent developments in the multiple myeloma (MM)  market. Topics covered include; positive topline results from the Phase III study ALCYONE of Johnson & Johnson’s and Genmab’s Darzalex (daratumumab) in combination with Velcade (bortezomib; Takeda), melphalan and prednisone (VMP) versus VMP alone, as front-line treatment for newly diagnosed patients who are not considered candidates for autologous stem cell transplantation; BioLineRx’s initiation of Phase III trial GENESIS assessing BL-8040, a highly-selective antagonist of the CXCR4 chemokine receptor, for the mobilisation of haematopoietic stem cells for autologous transplantation in patients with multiple myeloma; Cellectar Biosciences’ announcement of encouraging results from Phase I trial investigating CLR 131 in patients with relapsed/refractory multiple myeloma.

Business Questions:

• How does Johnson & Johnson’s and Genmab’s Darzalex compare to Empliciti (elotuzumab; Bristol Myers Squibb)?
• Is front-line treatment likely to be added to Darzalex’s label?
• Does data from ALCYONE support even broader use of Darzalex?
• How will varied use of the VMP regimen in Europe and North America affect the utilisation of Darzalex?
• Which patient types do KOLs expect to benefit from BioLineRx’s BL-8040?
• How does BL-8040 compare to Mozibil (plerixafor; Genzyme)?
• Is BL-8040 likely to demonstrate anti-tumour activity, and how will this affect commercial success?
• How do experts view early positive data for Cellectar Biosciences’ CLR 131?
• Do KOLs see a future for the drug conjugates approach in MM?
• What barriers to standard practice will radioactive drug conjugates face?


All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved